NEURIZON THERAPEUTICS LIMITED
ASX:NUZPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 95.9% of what they think they own, once every option and right converts.
Runway under 2 quarters; share count grew 61% in 24 months; 3 cash raises in 24 months
NEURIZON THERAPEUTICS LIMITED's ordinary share count rose 61.1% between November 2024 and September 2026, its latest share-count filing, to 792M shares. In that period, the company made three capital raises for total proceeds of A$25.8M, the most recent being a A$5.0M convertible note facility/placement in December 2025. Options and rights on issue could convert into 34M new shares, representing a 4.3% overhang of the current share count, of which 1% are in the money; the nearest expiry is February 2028. The company has under 2 quarters of funding at the recent spend rate. No proposed securities issues are currently pending.
Quick answers · 5
When did NUZ last raise capital?
The last capital raise in Neurizon Therapeutics's filings is Convertible Note Facility / Placement of $5.0M announced 23 Dec 2025, one of 3 cash raises in 24 months.
How much placement capacity does NUZ have left?
About 99% of the 15% placement capacity left, about 1% used in 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
How much cash does NUZ have?
In its quarterly cash report for the quarter ended 30 Sept 2026, Neurizon Therapeutics reported $11.4M of cash and estimated 4.5 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do NUZ's options expire?
Unexercised options and rights equal 4.3% of Neurizon Therapeutics's shares on issue; the nearest expiry is Feb 2028.
How much has NUZ's share count grown?
Neurizon Therapeutics has 791.7M shares on issue as at 28 Oct 2026, up 61.1% over 24 months according to its Appendix 2A filings.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 13 Oct 2026 | 3H · cancellation | NUZ : ORDINARY FULLY PAID | 791.7M | Appendix 3H |
| 15 Sept 2026 | 3H · cancellation | NUZ : ORDINARY FULLY PAID | 791.7M | Appendix 3H |
| 10 Sept 2026 | 2A · quoted issue | NUZ : ORDINARY FULLY PAID | 791.7M | Appendix 2A |
| 26 Aug 2026 | 2A · quoted issue | NUZ : ORDINARY FULLY PAID | 784.2M | Appendix 2A |
| 24 Aug 2026 | 3G · unquoted | NUZ : ORDINARY FULLY PAID | 775.1M | Appendix 3G |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
3 cash raises in the last 24 months · 2 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered17.9M · 2.3% of sharesOptions and warrants — they convert when the share price clears their exercise price.
- Condition-triggered16.2M · 2.1% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Exercise price on record: 17.9M priced (of which 5.9M in the money), 16.2M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
At $0.086 today, 5.9M securities are in the money (0.8% of shares on issue). At double today’s price it is 8.0M (1.0% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 16.2M (47.6% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| NUZAQ | Options | Price-triggered | $0.26 | 5 Feb 2028 | 384k | Filing |
| NUZAR | Options | Price-triggered | $0.20 | 30 June 2032 | 9.5M | Filing |
| NUZAB | Options | Price-triggered | $0.16 | 31 Aug 2033 | 2.0M | Filing |
| NUZAC | Options | Price-triggered | $0.059 | 31 Aug 2034 | 5.9M | Filing |
| NUZAG | Performance rights | Condition-triggered | — | — | 16.2M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
- NUZAAconvertible notes750k13 Oct 2026 Appendix 2A
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 14 Sept 2026 | Sergio Duchini | Buy on-market | 373k | 960k | — | $30k | 3Y notice |
| 30 June 2026 | Marcus Hughes | Buy on-market | — | — | — | $3k | 3Y notice |
| 29 June 2026 | Marcus Hughes | Buy on-market | — | — | — | $194 | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.